Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform, and a replay will be available on the Events & Presentations page of the company's investor relations website.
The appearance at the Guggenheim conference matters because it gives Helus Pharma a high-visibility forum to engage with institutional investors, analysts, and healthcare specialists at a time when the company is advancing its lead asset, HLP003, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status designed to expedite the development and review of drugs that may offer substantial improvement over existing therapies. The company is also developing HLP004 in Phase 2 for generalized anxiety disorder. Both programs target large unmet needs in mental health, where existing treatments often fail to provide durable relief.
For investors, the fireside chat offers an opportunity to hear directly from management about clinical timelines, regulatory strategy, and the commercial potential of NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The event comes as Helus Pharma, the commercial operating name of Cybin Inc., seeks to differentiate itself in a competitive psychedelics-adjacent sector. With operations in Canada, the United States, the United Kingdom, and Ireland, the company aims to improve the treatment landscape through NSAs that could provide durable improvements in mental health.
The conference participation also underscores the role of investor-facing platforms in raising awareness for clinical-stage biotech companies. Helus Pharma's full press release is available at https://ibn.fm/LrRvm, and additional company updates can be found through Helus Pharma's newsroom. The announcement was disseminated via InvestorWire, a communications platform within the Dynamic Brand Portfolio at IBN that provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers.
The webcast and replay availability mean that both live and later audiences can access management's commentary, potentially broadening the reach of the company's story beyond the conference room. For a company with Breakthrough Therapy Designation and a Phase 3 program, such exposure can be a catalyst for investor engagement and may help drive awareness of the unmet need in depression and anxiety treatments. Helus Pharma's participation in the Guggenheim conference is therefore more than a calendar item; it is a strategic opportunity to communicate its vision of helping minds heal through novel serotonergic agonists.


